Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome--a double blind, randomised clinical trial.

ABSTRACT:

Objectives

Fatigue is a major cause of disability in primary Sjögren's syndrome (pSS). Fatigue has similarities with sickness behaviour in animals; the latter mediated by pro-inflammatory cytokines, in particular interleukin (IL)-1, acting on neuronal brain cells. We hypothesised that IL-1 inhibition might improve fatigue in pSS patients; thus, we examined the effects and safety of an IL-1 receptor antagonist (anakinra) on fatigue.

Methods

Twenty-six pSS patients participated in a double-blind, placebo-controlled parallel group study. Patients were randomised to receive either anakinra or a placebo for four weeks. Fatigue was evaluated by a fatigue visual analogue scale and the Fatigue Severity Scale. The primary outcome measure was a group-wise comparison of the fatigue sco

SUBMITTER: Norheim KB 

PROVIDER: S-EPMC3254637 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature